{"title":"三分之一的患者在停用抗抑郁药后出现不良症状","authors":"","doi":"10.1002/pu.31211","DOIUrl":null,"url":null,"abstract":"<p>A systematic review and meta-analysis encompassing 79 studies has found that around one-third of patients who discontinue antidepressant medication will experience adverse symptoms, but only around 1 in 30 will experience severe discontinuation symptoms. An analysis of individual antidepressants found that imipramine, desvenlafaxine, and venlafaxine were associated with the highest incidence of discontinuation symptoms. Results were published online June 5, 2024, in <i>Lancet Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antidepressant discontinuation led to adverse symptoms one-third of the time\",\"authors\":\"\",\"doi\":\"10.1002/pu.31211\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A systematic review and meta-analysis encompassing 79 studies has found that around one-third of patients who discontinue antidepressant medication will experience adverse symptoms, but only around 1 in 30 will experience severe discontinuation symptoms. An analysis of individual antidepressants found that imipramine, desvenlafaxine, and venlafaxine were associated with the highest incidence of discontinuation symptoms. Results were published online June 5, 2024, in <i>Lancet Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31211\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Antidepressant discontinuation led to adverse symptoms one-third of the time
A systematic review and meta-analysis encompassing 79 studies has found that around one-third of patients who discontinue antidepressant medication will experience adverse symptoms, but only around 1 in 30 will experience severe discontinuation symptoms. An analysis of individual antidepressants found that imipramine, desvenlafaxine, and venlafaxine were associated with the highest incidence of discontinuation symptoms. Results were published online June 5, 2024, in Lancet Psychiatry.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
